Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections. Given the stock's underperformance this year, this news is a significant relief for investors. Let's delve into the trial's details, the stock's recent performance, and its future prospects.Get Gilead Sciences alerts:Gilead's Lenacapa ...

Gilead Sciences (GILD) shares soared 8.5% in the last trading session to close at $68.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.The surge is mostly attributable to positive results from the late study PURPOSE 1 wherein twice-yearly lenacapavir demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy.  On the basis of these results, ...

Key TakeawaysA Phase 3 trial of Gilead's injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women. Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants.More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval.Shares of Gilead surged Thursday following the news. Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

文章核心观点 - 两家制药公司Gilead Sciences(GILD)和Jazz Pharmaceuticals(JAZZ)的股价在2024年均有所下跌,远低于2015年的历史高点 [1][4][5] - GILD公司的长效HIV药物lenacapavir显示出优于公司日常药物Truvada的疗效 [3] - JAZZ公司的实验性药物suvecaltamide未能在中期试验中达到主要目标 [5] GILD公司总结 - GILD公司股价在2024年下跌15%,跌至2年低点62.07美元 [4] - 但GILD公司的长效HIV药物lenacapavir显示出优于公司日常药物Truvada的疗效 [3] - GILD公司股价远低于2015年的历史高点122美元以上 [4] JAZZ公司总结 - JAZZ公司股价在2024年下跌11%,远低于2015年的历史高点186美元 [5] - JAZZ公司的实验性药物suvecaltamide未能在中期试验中达到主要目标 [5] - JAZZ公司股价也远低于2022年8月31日的年度高点146.70美元 [5]

文章核心观点 - 吉利德公司的实验性每半年注射一次的预防艾滋病毒的药物在一项后期试验中100%有效 [1][2][3] - 这一结果使吉利德公司离推出新型艾滋病毒预防暴露前预防药(PrEP)更近一步,并扩大其在艾滋病业务中的地位 [3][6] - 长效注射剂可以帮助那些无法或不想每天服药的人预防艾滋病毒的传播,有望提高PrEP的使用率 [7][8][9][11] - 分析师预计吉利德公司的注射剂将大幅增加对预防艾滋病毒药物的需求,可能达到近20亿美元的峰值销售额 [12] - 吉利德公司需要确保该药物能够被低收入和中等收入国家获得,因为其现有艾滋病药物价格一直受到批评 [13][14] 公司相关 - 吉利德公司是一家专注于艾滋病业务的制药公司 [3][6][12] - 公司正在开发一种新型的每半年注射一次的艾滋病毒预防暴露前预防药(PrEP) [1][2][3][5] - 公司之前推出的Truvada是首个获批的PrEP药物,但目前市场上以每日口服药物为主 [6] - 公司的新PrEP药物Descovy去年销售约20亿美元 [12] - 公司计划分享如何让资源有限且艾滋病发病率高的国家也能获得该药物的更新信息 [14] 行业相关 - 长效注射剂PrEP有望提高PrEP的使用率,帮助遏制艾滋病毒的传播 [7][8][9][10][11] - 目前美国只有不到三分之一有资格使用PrEP的人在实际使用 [7] - 业内人士认为需要提供更多PrEP选择,以满足不同人群的需求 [4][9] - 分析师预计吉利德公司的注射剂将大幅增加对PrEP药物的需求 [12]

Gilead Sciences (GILD) closed at $63.56 in the latest trading session, marking a -1.21% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.23%. Elsewhere, the Dow saw a downswing of 0.17%, while the tech-heavy Nasdaq appreciated by 0.34%.The HIV and hepatitis C drugmaker's stock has dropped by 3.98% in the past month, falling short of the Medical sector's gain of 2.69% and the S&P 500's gain of 3.96%.Analysts and investors alike will be keeping a close eye on the perf ...

Grant & Eisenhofer, Jenner Law, Burg Simpson, and The Lawrence Law Firm are jointly issuing the following public statement following Gilead’s June 4th press release reported in the San Francisco Chronicle SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- In a recent press release (reported in The San Francisco Chronicle on June 4th), California pharma giant Gilead touts a $40 million settlement to resolve the lawsuits of approximately 2,625 plaintiffs. At the same time, it brushes off its culpability for del ...

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining. We're really pleased to have the Gilead team who has joined us virtually, unfortunately, due to the weather. It was hard to make it here in person. With us, we have Dan O'Day, Chairman and ...

These stocks offer great dividends and more.Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.Three Motley Fool contributors have found stocks with mouthwatering dividends that you can buy right now. Here's why they picked Gilead Sciences (GILD 1.33%), Organon (OGN 0.39%), and Pfizer (PFE -0.76%).A safe, reliable dividend payerProsper Junior Bakiny (Gilead Sciences): When looking for so ...